Genomind testing is a type of pharmacogenetic (PGx) test that analyzes your DNA to help predict how you might respond to certain psychiatric medications. The core product, called Genomind Professional PGx Express, looks at 26 genes involved in how your body processes and reacts to drugs commonly prescribed for depression, anxiety, ADHD, and other mental health conditions. The goal is to reduce the trial-and-error process of finding the right medication by giving your prescriber genetic data they can use alongside their clinical judgment.
How the Test Works
The test itself is simple. A healthcare provider orders it, and you provide a painless cheek swab sample, either at your provider’s office or through a kit sent to your home. Results come back in 3 to 5 business days, though patients on Traditional Medicare may wait up to 10 business days.
What comes back is a report your prescriber can use when choosing or adjusting medications. The report flags potential gene-drug interactions, identifies whether you metabolize certain drugs faster or slower than average, and highlights genetic factors that could increase your risk of side effects.
The 26 Genes and What They Tell Your Doctor
The genes on the panel fall into two categories, each answering a different question about how your body handles medication.
Pharmacokinetic genes affect how quickly your body breaks down a drug. Most of these involve the CYP450 enzyme family, a group of liver enzymes responsible for metabolizing a wide range of medications. If you’re a “fast metabolizer” for a particular enzyme, your body clears the drug quickly, potentially making it less effective at standard doses. If you’re a “slow metabolizer,” the drug builds up to higher-than-expected levels in your blood, raising the risk of side effects. The FDA labeling for citalopram (a common SSRI), for example, notes that slow metabolizers of one specific enzyme can see blood levels of the drug more than double, requiring a lower maximum dose to avoid heart rhythm problems.
Other pharmacokinetic genes on the panel affect drug absorption and transport across tissues rather than breakdown speed.
Pharmacodynamic genes influence how your brain and body actually respond to a drug once it arrives. These include genes related to serotonin transport, dopamine receptors, and an enzyme involved in folate processing (MTHFR) that plays a role in neurotransmitter production. For instance, certain variations in the serotonin transporter gene (SLC6A4) are associated with poorer responses to SSRIs, while MTHFR variants can affect whether adding a folate supplement improves outcomes for depression.
What the Test Is Designed For
Genomind markets its PGx test primarily for patients who have already tried medications that didn’t work or caused difficult side effects. It’s also positioned for people on multiple medications, those with chronic conditions requiring ongoing drug therapy, or anyone being considered for a medication that has published pharmacogenetic guidance. The conditions it touches most often are major depression, generalized anxiety, bipolar disorder, and ADHD, though the pharmacokinetic genes on the panel are relevant to drugs used across pain management, cardiology, and gastroenterology as well.
This is not a diagnostic test. It cannot tell you whether you have depression, anxiety, or any other condition. It tells your prescriber how your genetics might influence the way specific drugs behave in your body.
Evidence for Guided Treatment
A meta-analysis examining 735 patients with major depression found that those receiving pharmacogenetic-guided treatment had a 40% remission rate, compared to 25% in the unguided group. That translates to roughly 74% higher odds of achieving remission when genetic data informed prescribing decisions. A separate meta-analysis found a similar figure: depressed patients receiving PGx-guided care were 71% more likely to reach remission than those treated without genetic guidance.
In a study specifically evaluating Genomind’s earlier test (the Genecept Assay), patients whose treatment aligned with the test’s recommendations saw greater reductions in depressive symptoms, significant improvements in quality of life, and were twice as likely to achieve remission compared to those whose treatment didn’t follow the results. A naturalistic study of patients with mood and anxiety disorders found 87% showed clinically measurable improvement when treatment was guided by PGx data.
That said, insurers and independent reviewers have raised legitimate questions about whether the evidence is strong enough. Blue Cross Blue Shield of Rhode Island, in a 2025 policy review, concluded that the evidence was “insufficient to determine that the technology results in an improvement in the net health outcome.” The core concern is that genetic variation only explains a portion of why people respond differently to medications. Factors like other drugs you’re taking, your diet, kidney and liver health, and the nature of the condition itself all play significant roles. Demonstrating that a test predicts a certain metabolizer status is not the same as proving it changes real-world outcomes when used in clinical decisions.
Cost and Insurance Coverage
Depending on your insurance, the out-of-pocket cost ranges from $0 to $399. Medicare and Tricare cover the test completely. Medicaid covers it fully in Washington, D.C. and Virginia, with variable coverage in other states (Maryland Medicaid, for example, may require prior authorization). Private insurance coverage varies by plan and carrier, and some major insurers still consider the test not medically necessary, which can mean denied claims or higher out-of-pocket costs.
Professional PGx vs. Mental Health Map
Genomind offers two distinct products, and they serve very different purposes. The Professional PGx Express is a prescription test ordered by a licensed provider, analyzes 26 genes, and directly informs medication decisions. You cannot buy it on your own.
The Mental Health Map is a direct-to-consumer product you can order without a prescription. It analyzes 38 genes but does not provide any medication guidance. Instead, it looks at genetic predispositions across seven areas: eating behavior, sleep, habits and substance use, mood, focus and memory, social behavior, and stress and anxiety. While a few genes overlap between the two products, the interpretation is different. The Mental Health Map is a wellness product, not a clinical tool. It’s not intended to diagnose or treat any condition.
What the Test Cannot Do
Pharmacogenetic testing gives your prescriber one useful data point, not a complete answer. It cannot guarantee that a medication will work for you, and a “favorable” genetic result doesn’t mean you won’t experience side effects. Drug response depends on a web of factors: other medications (which can speed up or slow down the same enzymes the test measures), your age, weight, organ function, and the specific characteristics of your condition.
The test also only covers the genes and drugs on its panel. If you’re prescribed something not included in the report, the results won’t help. And because the science of pharmacogenomics is still evolving, some gene-drug relationships on the panel have stronger clinical evidence behind them than others.